Elivaldogene Autotemcel (Skysona) — CPB 1017 | AETNA Coverage Update

Aetna modified CPB 1017 for elivaldogene autotemcel (Skysona), effective September 26, 2025. Here's what billing teams need to do.

Aetna, a CVS Health company, updated CPB 1017 — its coverage policy for elivaldogene autotemcel (Skysona), a gene therapy for X-linked adrenoleukodystrophy (X-ALD). The modification affects precertification requirements, site-of-care rules, and a 40-code billing stack that spans stem cell harvesting, infectious disease screening, and IV infusion administration. If your practice or facility handles gene therapy, this policy change touches your workflow before the first claim ever goes out.

Quick-Reference Table

Aetna Elivaldogene Autotemcel Coverage Criteria and Medical Necessity Requirements 2025

The Aetna Skysona coverage policy under CPB 1017 Aetna system targets a narrow patient population: members with X-linked adrenoleukodystrophy. The ICD-10 codes in scope are E71.520 (childhood cerebral X-ALD), E71.521 (adolescent X-ALD), E71.528 (other X-ALD), and E71.529 (X-ALD, unspecified). If your patient's diagnosis doesn't map to one of those four codes, don't expect coverage to move forward.

Medical necessity is a hard gate here. Aetna requires precertification of elivaldogene autotemcel for all participating providers and members in applicable plan designs — no exceptions listed. Contact National Medical Excellence (NME) at 877-212-8811 to initiate that process. Waiting until the patient is on your schedule is too late for a gene therapy with this many upstream requirements.

The prior authorization requirement is explicit, and the routing is specific. NME handles this — not the standard Aetna clinical prior auth line. If your team routes Skysona precertification through the wrong channel, you'll lose time and create a documentation gap that can trigger a claim denial downstream.

The coverage policy also includes a site-of-care restriction. Gene and cellular therapies must be administered at an Aetna Institutes® Gene Based, Cellular and Other Innovative Therapy (GCIT®) Network facility — unless the member's plan has specifically opted out of that requirement. Check the Aetna Institutes GCIT Designated Networks list before you book the infusion. Reimbursement for Skysona administered at a non-GCIT facility is at serious risk.

This is the same pattern Aetna has used on other advanced gene therapies. The payer is centralizing delivery at specialized centers to manage both clinical outcomes and cost exposure. For billing teams, that means site-of-care verification is now part of your pre-claim checklist.

Coverage Indications at a Glance

Aetna Elivaldogene Autotemcel Billing Guidelines and Action Items 2025

The Skysona billing workflow is more complex than a standard drug infusion. You're managing a 40-code CPT stack, one HCPCS code, infectious disease screening, metabolic labs, and a site-of-care requirement — all before the infusion codes for CPT 96365–96368 even come into play. Here's how to handle it.

If your facility is new to Skysona billing or you're unsure how the GCIT requirement interacts with your current contracting, loop in your compliance officer before you bill the first case. The financial exposure on a single gene therapy claim is substantial, and the documentation requirements are not forgiving.

CPT, HCPCS, and ICD-10 Codes for Elivaldogene Autotemcel Under CPB 1017

CPT Codes Related to CPB 1017

HCPCS Codes Related to CPB 1017

Key ICD-10-CM Diagnosis Codes